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PART  ONE
1INTRODUCTION
         Today glaucoma is the second most common cause of blindness.
Glaucoma is the most common cause of irreversible blindness in the
world. The world health organisation estimates (2002) that number of
people who have become blind because of glaucoma were 4.4 million
(12.3% of the blind world wide) population based studies have
estimated that the prevalence of glaucoma in India to be about 11.9
million and 60.5 million in the world in 2010.
         Glaucoma is defined as a disturbance of the structural or
functional integrity of the optic nerve that can usually be arrested or
diminished by adequate lowering of Intraocular pressure (IOP).1
         Traditionally glaucoma has been classified as primary and
secondary forms. Within this large group of glaucoma, primary open
angle glaucoma is the most common form.
CLASSIFICATION OF GLAUCOMAS
         The major classification of the glaucomas relates to the
configuration of the anterior chamber angle and the age of onset of the
disease. Glaucomas are classified in to:
21. Open angle glaucoma -
a.  Primary open angle glaucoma
b.  Normal tension glaucoma
c. Juvenile glaucoma
d. Ocular hypertension
e. Secondary open angle glaucoma
2.  Angle closure glaucoma -
a. Primary angle closure glaucoma
b. Secondary angle closure glaucoma either with or without
pupillary block
3. Childhood glaucoma -
        a. Primary congenital or infantile glaucoma
        b. Glaucoma associated with congenital anomalies
        c. Secondary glaucoma in infants and children
            Primary open angle glaucoma is explicitly characterised as
multifactorial optic neuropathy with a characteristic acquired atrophy
of the optic nerve and loss of retinal ganglion cells  and their axons
developing in the presence of open anterior chamber angles and
manifesting characteristic visual field abnormalities. Other types of
glaucoma invariably the secondary glaucoma, historically even the
3primary angle closure glaucoma are defined first and foremost by
presence of elevated IOP1,2
         A certain percentage of the general population responds to
repeated instillation of systemic or ocular corticosteroid with a variable
increase in IOP. The people who manifest this response to long term
steroid therapy whether given by the topical, systemic, periocular or
intra ocular route and IOP elevation can lead to glaucomatous optic
atrophy and loss of vision. Such a condition is referred to as steroid
induced glaucoma.1,2
SECONDARY OPEN ANGLE GLAUCOMA
1. Pigmentary glaucoma
2. Exfoliation syndrome
3. Corticosteroid glaucoma
4. Lens induced glaucoma
         a. Phacolytic glaucoma
         b. Lens particle glaucoma
         c. Phacoanaphylaxis
45. Glaucoma after cataract surgery
6. Glaucoma after trauma
7. Glaucoma associated with intraocular hemorrhage
8. Retinal detachment and glaucoma
9. Glaucoma after vitrectomy
10. Glaucoma with uveitis
11. Intra ocular tumors and glaucoma
12. Amyloidosis
13. Elevated episcleral venous pressure
       Approximately 30% of the patients on topical therapy may be
affected.25% responders of the general population respond to steroid
and elevation in IOP after 4 weeks of usage of steroid, 5% of the
population were high responders. They show 10 to 15 mm of Hg
greater, may develop IOP rise within 2weeks.
5HISTORICAL  REVIEW
First case of steroid induced glaucoma was recognised by
E.S.PERKINS in 1957. The patient was treated for  chronic chorio
retinal inflammatory disease with cortisone 25 mg daily for few
months. IOP reduced after stopping steroids.
             In 1954 cases of similar nature were noted by Francois. In
1955 Laval and Collier noted some cases of steroid induced glaucoma.
              In 1958 Covell reported three cases of glaucoma occurring in
patients receiving steroid therapy for arthritis.
              In 1963 Becker and Mills showed local application of steroids
can cause rise in IOP. In 1963 Armaly has suggested that cortisone
known to have some effect on mucopolysaccharides and increase in
resistance to outflow, which could be due to swelling of this layer,
perhaps viscosity of this layer.15,18,23
           In 1964 Becker and Hahn showed response to steroid had
genetic basis
6STAGES OF GLAUCOMA
STAGE : 1  initiating events
STAGE : 2  structural alterations
STAGE : 3  functional alterations
STAGE : 4  retinal ganglion cell and optic nerve damage
STAGE : 5 visual loss
STAGE : 1
         Includes the condition or series of condition that sets in motion
the chain of events (optic nerve damage/visual loss) but it is preceeded
by pathological or physiological alterations.
STAGE : 2
       Tissue changes which preceeds but may eventually lead to
alterations in aqueous humor dynamics and optic nerve head function.
STAGE : 3
         Functional alterations and physiological abnormalities leading to
optic nerve damage.
STAGE : 4
         Loss of axon as a result of  events in stage2 and stage3
STAGE : 5
         Vision loss due to nerve fibre layer and axonal damage
glaucomatous field loss.1
7ANATOMY OF ANGLE ANTERIOR CHAMBER
         The angle is bound at anterior side by the peripheral part of
cornea, the trabecular meshwork, the anterior face of the ciliary body
and posterior wall is formed by the iris. The scleral groove lies
between the scleral spur posteriorly and anterior border ring of
schwalbe’s line anteriorly, which is occupied by canal of schlemm and
trabecular meshwork.
TRABECULAR MESHWORK
          It is a triangular structure, the apex of which blends with the
termination of descemet’s membrane and deep corneal lamellae. The
base of the triangle is attached to the anterior surface of scleral spur,
anterior surface of ciliary body and root of the iris. The scleral sulcus is
converted in to a circular channel called schlemm’s canal by the
trabecular meshwork.
            Histologically it is composed of lamellae, made up of a central
core consisting of ground substance collagenous and elastic like fibres,
surrounded by a single layer of endothelial lining that is supported by a
basement membrane. The anterior part of meshwork is non filtering
and posterior filtering part is divided in to 3 portions.
81. UVEAL MESHWORK:
         This portion adjacent to the anterior chamber are arranged in
bands that extend from the iris root and ciliary body and extend to the
peripheral cornea. This contains irregular openings ranging in size
from 25-75 microns. This is the innermost part of the trabecular
meshwork.
2. CORNEO SCLERAL MESHWORK:
          This portion extends from the scleral spur to the lateral wall of
scleral sulcus. The openings varying from 5 to 50 microns become
progressively smaller as the schlemm’s canal is approached.
3. JUXTA-CANALICULAR TISSUE:
             It is a thin layer of tissue 2-20 microns thick, the outermost
portion of the meshwork adjacent to the schlemm’s canal.
AQUEOUS VEINS
          They are exit channels of aqueous first described by ascher.
They vary in size from 0.01-0.1mm and interconnect schlemm’s canal
and episcleral veins.1,4
ANATOMY OF TRABECULAR MESHWORK
AQUEOUS OUTFLOW PATHWAY
9INTRAOCULAR PRESSURE [IOP]
Normal intraocular pressure may be defined as the pressure that
does not lead to glaucomatous damage of the optic nerve head.
Unfortunately, such a definition cannot be expressed in precise
numerical terms, in that all eyes do not respond the same to given
pressure levels.
Three factors determine IOP :
-   Rate of aqueous humor production
- Resistance to aqueous outflow across trabecular
meshwork to schlemm's canal
-    Level of episcleral venous pressure
FACTORS EXERTING LONG-TERM INFLUENCE ON IOP
1.  GENETICS: The IOP within the general population
appears to be under hereditary influence, through a
polygenic, multifactorial mode of inheritance.
2.  AGE: There is an increase in IOP with age.
3.  GENDER: IOP is equal between the sexes in the age
group of 20-40 years. In older age groups, the apparent
increase in mean IOP with age is greater in women.
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4.   REFRACTIVE ERROR: A positive correlation exists
between IOP and both axial length of the globe and
increasing degrees of myopia.
5.   ETHNICITY: Blacks have higher IOP than whites.
FACTORS EXERTING SHORT-TERM INFLUENCE ON IOP
1.   DIURNAL VARIATION:
The intraocular pressure is subject to cyclic fluctuations
throughout the day. The reported mean amplitude of daily
fluctuation ranges from approximately 3mm of Hg to 6
mm of Hg. An amplitude greater than 10 mm of Hg is
generally considered pathological. Many people reach
their peak pressures in the morning hours, but others do so
in the afternoon, in the evening or during sleep. The
primary clinical value of measuring diurnal IOP variation
is to avoid the risk of missing a pressure elevation with
single readings. The intraocular pressures are recorded 6
times during the day at 4 hourly intervals and the graph is
plotted connecting all points.
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2.  POSTURAL VARIATION:
The IOP increases from sitting to the supine position with
reported average differences of 0.3-6 mm of Hg.
3.   EXERTIONAL INFLUENCE:
Prolonged exercise such as running lowers the IOP.
Valsalva maneuver increases the IOP.
4.  LID MOVEMENT:
Blinking has been shown to rise the IOP.
5.  INTRAOCULAR DISEASES:
Anterior uveitis and retinal detachment are associated
with a reduced IOP.
6. SYSTEMIC CONDITIONS:
Systemic hypertension and hyperthermia are associated
with elevated IOP. The IOP has been reported to be lower
with hyperthyroidism and higher with hypothyroidism.
Diabetic patients have been reported to have higher IOP
than the general population.
GOLDMANN APPLANATION TONOMETRY
12
7.  ENVIRONMENTAL CONDITIONS:
Cold air reduces the IOP.
8. HORMONAL FACTORS:
Accumulation of corticosteroids topically, periocularly
and systemically increases IOP. IOP varies with the
menstrual cycle. It is low in the third trimester of
pregnancy. Pharmacological doses of progesterones and
estrogen reduced intra ocular pressure in experimental
animals and man. Hormone replacement therapy in
women has no effect on  IOP. However esterified estrogen
with methyl testosterone therapy does rise IOP.
9.  GENERAL ANAESTHESIA:
It is usually associated with reduction in IOP. Drugs like
ketamine and succinyl choline cause a transient rise in
IOP.
10. OTHERS:
Alcohol and Heroin decrease the intraocular pressure
whereas LSD and corticosteroids increase the intraocular
pressure.1
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PATHOGENESIS OF GLAUCOMATOUS OPTIC ATROPHY
The pathogenesis of glaucomatous optic atrophy has remained
the matter of controversy since mid 19th century.
The mechanical theory was proposed by Muller in which the
elevated IOP led to direct compression and death of the neurons.
The vasogenic theory was proposed by Von-Jaeger. According
to this theory the structural and functional defects occurring in
glaucoma are due to ischemia. The most elaborate support for this
theory was advanced by HAYREH. He proposed that both an increase
of IOP and fall of blood pressure lead to fall of perfusion in the ocular
vessels.
PATHOGENESIS OF OPTIC NERVE HEAD CHANGES
IN GLAUCOMA
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The fall of perfusion pressure can obliterate vessels first in the
post laminar and retrolaminar region. The blood flow in the pre-
laminar and post-laminar region and the choroid lack the ability of
autoregulation. Optic cupping results from chronic ischemia of the
optic nerve head.
There are two weak points in the above theory. According to
HAYREH the primary site of axon damage is the prelaminar disc area,
but it has been found that it is actually in the lamina cribrosa region.
There is evidence in favour of effective autoregulation of blood flow in
the optic nerve head. Thus, Glaucomatous damage to the optic nerve is
multifactorial and is affected by more than just IOP elevation.1,2,5
STRUCTURAL CHANGES OF GLAUCOMATOUS
OPTIC ATROPHY
1.      FOCAL ATROPHY
2.      CONCENTRIC ATROPHY
3.      DEEPENING OF THE CUP
4.    ADVANCED GLAUCOMATOUS CUPPING
FUNDUS CHANGES IN GLAUCOMA
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VASCULAR SIGNS OF GLAUCOMATOUS OPTIC ATROPHY
a.  SPLINTER HEMORRHAGES
b.     BARING OF THE CIRCUMLINEAR VESSEL
c.     NASALISATION OF VESSELS
d.     BAYONETING OF THE VESSELS
VISUAL FIELD LOSS IN GLAUCOMA
1.      PERIPHERAL LOSS
2. LOCALIZED NERVE FIBER LAYER DEFECTS:
3.      ARCUATE DEFECTS
4.      NASAL STEP
5.      EARLY GLAUCOMATOUS FIELD DEFECTS
a.Concentric contraction
b.Angioscotomata
 6.    ADVANCED GLAUCOMATOUS FIELD DEFECTS
          a.Double arcuate scotoma
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STEROID INDUCED GLAUCOMA
The response to long term Steroid therapy whether given by the
topical, systemic procedure or intraocular route and the IOP elevation
can lead to glaucomatous optic atrophy and loss of vision, such a
condition is called as Steroid induced glaucoma.1
The clinical picture resembles that of chronic open angle
glaucoma with an open normal appearing anterior chamber angle and
absence of symptoms.
Approximately one third of the individuals experience moderate
increase in IOP after topical steroid use. However 5-6% of normal
population develops a marked increase in IOP after 4-6 weeks of
topical steroid therapy. Thus 5% of the general population is
considered to be “steroid responders” i.e they may develop steroid
induced glaucoma when steroids are administered. This was shown by
studies conducted by Armaly and Becker13.
IOP Response to topical Corticosteroid  administration
Armaly Becker
Frequency QID TDS
Duration 6 weeks 4 weeks
Parameter Final IOP IOP change
Type of responder IOP mm Hg IOP mm Hg
Low < 20 (58%) < 6 (66%)
Intermediate 20-31 (36%) 6-15 (29%)
High > 31 (6%) > 15 (5%)
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ETIOPATHOGENESIS
Various theories has been put forth to describe the mechanism of
steroid induced glaucoma
i. Nuclear transport of Glucocorticoid receptor :
Glucocorticoids have been shown to alter trabecular meshwork
cell morphology by causing an increase in nuclear size and DNA
content. Experiments on culture human trabecular meshwork cells
exposed to dexamethasone have demonstrated that FK 506 binding
immuno protein FK BP5, mediates nuclear transport of human
glucocorticoid receptor GR Beta suggesting that this play a role in his
increased glucocorticoid responsiveness.
ii. Influence on Extra Cellular Matrix :
Francois postulated that glycosaminoglycans in the polymerized
form become hydrated, producing a biologic oedema that may increase
resistance to aqueous outflow. Hyaluronidase in lysosomes
depolymerise hyaluronate, corticosteroid stabilize the lysosomal
membrane which may lead to an accumulation of polymerized
glycosaminoglycans in the trabecular mesh work.
iii. Influence on Phagocytosis :
Endothelial cells lining the trabecular meshwork have
phagocytic properties which may help to clean the aqueous of debris
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before it reaches the inner wall of Schlemm’s canal. Corticosteroid are
known to   suppress phagocytic activity and suppressed phagocytosis
of the trabecular endothelium may allow debris in the aqueous to
accumulate in the meshwork and act as barrier to outflow.
iii. Genetic Influences :
Multiple genes that may be involved in protective and damaging
mechanisms with IOP elevation that are unregulated with
dexamethasone (in addition to myocilin) ?1- antichymotrypsin,
Pigment epithelium derived factor, cornea derived transcript 6,
Prostaglandin D2 Synthase, Growth  arrest specific decorin, Insulin like
growth factor binding protein – 2, Ferritin light chain, Fibullin-1C1.
          In an experiment involving exposure of cultured trabecular
meshwork cells to dexamethasone, delayed increase in expression of a
gene product was observed. This protein was termed as “trabecular
meshwork inducible glucocorticoid response” protein initially
localized  to GLC1A locus on chromosome 1q 25, subsequently linked
to the myocilin gene (MYOC).
MYOC gene spans approximately 17 Kb and contains three
exons transcripting 2-3 kb gene product. Within the trabecular mesh
work, it is equally expressed in the trabecular mesh work cells from the
juxtacanalicular, corneoscleral and uveal layers. Normal myocilin
expression increased in response to elevated IOP, dexamethasone
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exposure and other forms of trabecular stress implying that it may have
a protective role in outflow pathway. However recent study conducted
in steroid responders failed to identify a statistically significant
association between myocilin variations and steroid response13.
Histopathology :
Light microscopy demonstrated accumulation of
glycosaminoglycans  that was best demonstrated by the Colloidal iron
Stain, but was also seen with alcain blue.
Light microscopy revealed excessive accumulation of melanin
pigment aggregates which were distributed through out trabecular
meshwork involved juxta canalicular meshwork (JCM) and the
endothelium lining Schlemm’s canal.
The excessive pigmentation appeared to obscure the amount of
acid mucopolysaccharide glycosaminoglycans (GAG). Endothelial
lining of trabecular meshwork with Ruthenium red lining compared
with control untreated eye. Electron microscopy showed an increase in
glycosaminoglycans by Ruthenium red stain in the corticosteroid
treated eye in contrast to control untreated eye.
Demonstration of acid mucopolysaccharide was confirmed in
the tissue cultures of the trabecular meshwork in rabbit and pig eyes.
Electron microscopically glycosaminoglycans were identified
using colloidal iron stain, this was demonstrated by Armaly and Wang
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in Rhesus monkey, while Futa & Coworkers stained it in human
trabecular meshwork.
Ruthenium positive deposits have been recently demonstrated in
trabeculectomy specimen in chronic open angle glaucoma.
Rohen and associates described amorphous fibrillar material in
the juxtacanalicular meshwork in two cases of glaucoma induced by
topical administration of corticosteroids45.
Glucocorticoid administration increases the expression of
collagen elastin and fibronectin within the trabecular meshwork and
induces expression of Sialoglycoprotein. Steroid use decreases
expression of extracellular proteinases inducing fibrinolytic enzymes
and stromolysin.
Ultra structural changes in the trabecular mesh work :-
    The main finding in the steroid induced glaucoma is an
accumulation of basement membrane like material staining for type IV
collagen.
Glucocorticoids affect trabecular meshwork cell morphology by
increasing synthesis of endoplasmic reticulum, golgicomplexes and
secretory vesicles.Cell and nuclear size increases deposition of
extracellular matrix and thickens the trabecular beams. This increases
the expression of fibronectin and laminin.5
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STEROID PROVOCATIVE TEST:
Steroid provocative test with dexamethasone was advised and
tried. The pressure rose to 30 mm of Hg, visual field deteriorated
substantially. After stopping steroid administration pressure remained
elevated falling only to 21 – 27 mm of Hg. IOP does not fall to normal
range. Post operative IOP correlates well with the level of serum
hydrocortisone. Moreover a recent study has found a close relation
between diurnal fluctuation of IOP and level of corticosteroid.
METHOD:
           Topical dexamethasone 0.1% suspension was given to the right
eye three times daily for a period of 4 weeks. At the end of 10 wks
applanation tonometry was done.
PLASMA CORTISOL:
Hydro cortisone is a steroid hormone released in response to
stress and low level of blood glucocorticoids. Its primary functions are
to increase blood sugar through gluconeogenesis, suppress the immune
system, aid in fat, protein and carbohydrate metabolism.
The amount of cortisol present in the blood undergoes diurnal
variations, level peaks in the early morning (approximately 8 am) and
reaches its lowest level at about midnight to 4am or 3 to 5 hours after
the onset of sleep.
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Plasma cortisol AM level:4.0 to 22 microgram/decilitre
Plasma cortisol PM level:3.0 to 17 microgram/decilitre
In steroid induced glaucoma patients plasma cortisol levels were
rised both in the morning and night.
MECHANISM OF RISE OF IOP
An explanation for the apparently conflicting interpretations
may be that corticosteroids may have biphasic effect. An increase  in
circulating corticosteroid may cause an increase  in aqueous inflow
whereas topical administration of this medication will produce a
decrease in aqueous outflow. This differential effect may be atleast
particularly a factor of vehicle used with topical medication, as several
studies have implicated the vehicle as the agent which itself would be
responsible for elevation of IOP.
The hypothesis that acute elevation of IOP may result from
systemic administration of steroid and chronic glaucoma from topical
usage was suggested by Grieten and Collignon Brach in 1965.
Systemic corticosteroids have been observed to cause a rapid increase
in IOP which fall quickly upon elimination of steroid.
In contrast, topically administered corticosteroids even in large
doses does not seem to cause a pressure increase  in period shorter than
1 week. The duration of administration may also play a role in
determining the mechanism of elevation of pressure. As noted before
the rise of pressure secondary to topical use of steroids requires several
23
weeks or more to develop. It may be, that the quicker type of response
is related to an increase in aqueous inflow mediated by presence of
hormone itself. In contrast, the more prolonged effect is a reflection of
interference with aqueous outflow, perhaps due to structural
alteration45.
Routes of Administration :
i. Topical therapy :It occurs more often with topical therapy.
fluorometholone 25% is less likely to increase IOP  in
corticosteroid responders.
ii. Periocular therapy – Periocular injection of a long acting
corticosteroid is the most dangerous routes of
administration from the stand point of steroid induced
glaucoma.
iii. Intravitreal Therapy : Injection of triamcinolone acetonide
increases the IOP by several mm of Hg in about half of
the patients treated with 2 to 4 weeks after the start of
treatment.
iv. `Placement of depot steroid implant in the vitreous has
also been reported to produce serious elevation of IOP in
large percentage of patients.
v. Systemic therapy: Systemic administration of
corticosteroids is least likely to induce glaucoma.
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ROUTES OF ADMINISTRATION LEADING TO STEROID
INDUCED GLAUCOMA
Exogenous Corticosteroid:
Topical:
Ocular eye drops
           Ocular Ointments
Inadvertent administration to eye from lids or face.
Periocular intravitreal injection
Systemic :
Oral
Injectable
Endogenous Corticosteroids
Adrenal hyperplasia
Adrenal adenoma
Ectopic ACTH Syndrome
After intravitreal triamcinolone, IOP rises in 50% of the eyes when
compared with 1-2 months of injection of systemic corticosteroid. IOP
rise was less with
i) Parenteral route
ii) Inhalational route of administration.
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CLINICAL FEATURES :
Very few Symptoms exist
? History of use of steroids present
? History of systemic or ocular disease which could require
chronic corticosteroid use (uveitis, collagen vascular disease,
bronchial asthma).
? Age of the patient is important
Infants may present with features of watering, photophobia,
Blepharospasms, cloudy cornea, elevated IOP, Optic disc
cupping like  Buphthalmos, but  unlike congenital glaucoma,
angle of anterior chamber is normal.
? Teenager, adults presents features of primary open angle
glaucoma.
Clinical evaluation reveals an elevated IOP, open and normal
appearing angles on gonioscopy, painless white eye and optic disc
cupping and visual field defects.
Steroid induced glaucoma may mimic low tension glaucoma
when the Steroid induced pressure elevation has damaged the optic
nerve visual field in the past, but IOP subsequently reduced to normal
with cessation of steroid.
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Steroid induced glaucoma may be masked following refractive
surgery due to central corneal thinning, Ocular rigidity changes,
Corneal oedema or fluid accumulation beneath Lasik flap.
Associated ocular finding from use of topical steroids include
mydriasis, increased corneal thickness, corneal ulcers, posterior
subcapsular cataracts, delayed wound healing, ptosis and skin atrophy
of eyelids.
Eyes with vernalkeratoconjunctivitis (VKC) with and without
glaucoma had similar corneal topography, increased IOP  associated
with steroid induced glaucoma and vernalkeratoconjunctivitis (VKC)
may contribute to an increase in corneal curvature and posterior
corneal elevation. Changes may be reversed by a reduction in the IOP
with medical therapy.
Differential Diagnosis
1. Primary Open Angle Glaucoma
2. Uveitic Glaucoma
3. Glaucomatocyclitic Crisis
4. Normal tension glaucoma
5. Traumatic glaucoma (especially unilateral cases)
6. Juvenile glaucoma
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MANAGEMENT :
1. Discontinuation of steroid use :-
? Discontinuation of the use of steroid is the first line of
treatment.
? Stoppage of steroid normalises the IOP with in 1 to 4
weeks.
? Acute resolution occurs in some cases within days of
stoppage of steroid.
? Duration of steroid therapy also appears to influence the
reversibility to IOP elevation.
? Administration of anti glaucoma drugs till IOP decreases
to the normal level.
? Lower potency drugs like fluorometholone, loteprednol,
rimexolone, medrysone have lesser chances of increasing
IOP.
2. Excision of Depot Steroid :
? In all cases where depot steroid appears to be responsible
for the rise in IOP, the optimal treatment if the medical
management fails, is to excise the depot steroid.
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? Topical steroids prescribed should be under the
monitoring of an ophthalmologist.
3. Glaucoma therapy :
? Topical beta Blockers/aqueous suppressants
In eyes with steroid induced glaucoma due to Vernal Kerato
Conjunctivitis prostaglandins should be avoided.
4. Anecortave acetate is a synthetic  derivative of cortisol but very
specific and irreversible chemical modifications to the cortisol
structure have resulted in creation of a potent inhibitor of blood
vessel growth with no evidence nonclinically or clinically of
glucocorticoid receptor bioactivity.
Anterior juxtascleral depot of AA (Anecortave Acetate) has been
shown to lower IOP substantially in some eyes with medically
controlled steroid related ocular hypertension.13
5. Selective laser trabeculoplasty:
This is also used in the treatment of steroid induced glaucoma.
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SELECTIVE LASER TRABECULOPLASTY
Selective laser trabeculoplasty is a new technology being
introduced in the clinical practice of ophthalmology.
It was further developed by medical company (lumenis), with
work done by Dr.Latina in 1995. SLT was introduced worldwide and it
was cleared by the food and drug administration in march 2001. The
key concept in the design of this laser system was to direct the energy
towards only pigment containing cells in the trabecular meshwork.12,20
MECHANISM OF SELECTIVE LASER TRABECULOPLASTY
Dr.Jonge A.Alvarado of university of California, San Francisco
explained  the mechanism of Selective laser trabeculoplasty (SLT)  and
its practical implications.
Trabecular meshwork endothelial cells act as pressure sensors,
when detecting increased IOP they secrete soluble factors namely
cytokines into the aqueous humor. These cytokines induce longterm
increase in permeability of schlemm’s canal endothelial cells and thus
the IOP is reduced.
SELECTIVE  LASER TRABECULOPLASTY
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         When SLT irradiation is applied to the trabecular endothelium it
recruits monocytes of the innate immune system. These cells in turn
activate the trabecular endothelium cells causing the secretion of
cytokines. These cytokines as shown microscopically increase the
porosity of schlemm’s canal endothelium thus reducing the IOP. It is
likely that the monocytes also secrete cytokines which affect the
porosity directly.39
            It is effective for steroid induced glaucoma, reduces the mean
intra ocular pressure by 30% more effective following
intraocularpressure rise due to intravitreal triamcinolone.
Laser pulse duration is fixed at 3 nano seconds. The spot size is
fixed at 400micrometre,which encompasses the entire meshwork from
schwalbe’s line to the ciliary body band. The laser energy is uniformly
distributed to evenly treat the meshwork.
            The power is adjustable from0.3 to 2.0 millijoule. The end
point for the selective laser trabeculoplasty energy setting is the
appearance of a tiny cavitation bubble and/or slight blanching of the
trabecular meshwork. The energy can be increased from 0.6 to1.2milli
joule.100 confluent applications were given per quadrant. It is usually
performed for two quadrants (180 degrees) or for four quadrants
(360 degrees) 20,21
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6. Trabeculectomy and glaucoma drainage device in
uncontrolled glaucoma.
7. External trabeculotomy:
External trabeculotomy has been useful in treating steroid
induced glaucoma. Fewer complications have been associated with this
procedure. Various studies have proved the long time effect of this
procedure on steroid induced glaucoma.28
STEROID INDUCED GLAUCOMA AND REFRACTIVE
SURGERY
Steroid induced glaucoma is known to be masked following
refractive surgery as IOP recordings are erroneous due to central
corneal thinning, ocular rigidity changes, corneal oedema or fluid
accumulation beneath the LASIK flap. Early onset steroid induced
elevation of IOP after LASIK may cause corneal oedema and a sudden
decrease in visual acuity. Rapid diagnosis and treatment can control
IOP and recovers visual loss.
Steroid induced glaucoma has been reported after photo
refractive keratectomy and is known to be under diagnosed for same
reason.
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PREVENTION :
i) Patient Selection :
Individuals with chronic open angle glaucoma and/or with the
family history of the disease are more likely to respond to long
term steroid therapy than other persons.
Patients with the following risk factors should be screened for
glaucoma. The risk factors include myopic eyes, Diabetes
mellitus, connective tissue disorder.
ii. Drug Selection :
When corticosteroid is required for any disorder, optimum drug
is the one, that can achieve the desired therapeutic response by
the safest route of administration in the lowest concentration and
fewer potential side effects.
Careful monitoring of all patients on corticosteroid especially
those with family history of glaucoma is warranted. Self
medication and injudicious use of steroids should be avoided. If
necessary steroid therapy must be used with intermittent drug
holiday and never on continuous basis. 13
PART  TWO
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AIMS OF THE STUDY
1. To analyse the clinical presentation and etiological risk
factors in steroid induced glaucoma and duration and type of
steroid used.
2. To establish the diagnosis and analyse about the management
options in steroid induced glaucoma.
3. To know the response of selective laser trabeculoplasty in
treatment of steroid induced glaucoma patients.
Inclusion Criteria
1. Patients with the history of steroid use either topically or
systemically.
2. Persistent elevation of IOP more than 21mm of Hg or disc
suspicious of glaucomatous damage.
3. Gonioscopically open angles.
Exclusion Criteria
1. Normotensive glaucoma
2. Narrow angle glaucoma
3. All other secondary glaucomas
4. Developmental glaucoma
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Materials and Methods
The study was a prospective study conducted at glaucoma
services at Regional Institute of Ophthalmology from the period
between June 2009 – October 2011.
The study was done in 43 patients of established steroid induced
glaucoma after complete evaluation.
A detailed history regarding the type of steroid used, mode of use,
reason for use, and duration of use was recorded. The risk factors of
family history of glaucoma, primary open angle glaucoma, Diabetes
mellitus, hypertension, high myopia and connective tissue disorders
were also asked in detail from the patients.
Patients were enquired about defective vision, defective field of
vision and frequent change of glasses.
Visual acuity was recorded and refraction was done in all cases to
correct refractive errors. Ocular examination of both eyes with slit lamp
was done to rule out other causes of glaucoma and to know about the
lens changes. Gonioscopy was done using single mirror Goldmann
gonioprism and angles were graded by using shaffers grading method.
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Intra ocular pressure was measured using Goldmann applanation
tonometer and corrected to the central corneal thickness as measured by
pachymetry.
Fundus examination was done using +90D slit lamp
biomicroscopy and the cup, disc ratio was noted. Associated vascular
signs like Nasalisation, Bayonetting, Laminar dot sign, Baring of
circumciliary vessels and Splinter hemorrhages near the disc were
noted.
Diurnal variation test (phasing) was done in all the patients by
recording 6 readings each 4 hrs apart throughout the day plotting the
graph connecting all the points. The recording was done using Perkins
applanation tonometer.
Field charting was done by computer assisted static automated
perimetry, (Octopus 123, G1X program TOP strategy) for both the eyes.
Reliable field testing with false positives and false negatives below 30
percent were taken for the study.
Unnecessary usage of steroids was curtailed initially and the
patients were followed up regularly. Certain patients with connective
tissue disorders were on maintenance dose of steroids as advised by the
rheumatologist. Patients were treated according to the amount of
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glaucomatous damage. Then the patients were reviewed frequently and
followed up regularly in equal intervals.
Plasma cortisol levels were measured at 8 am in the morning and
8pm in the evening for 10 patients.
Selective Laser Trabeculoplasty was performed for 10 patients.
The patients who showed progress of glaucoma even after medical
therapy were chosen for selective laser trabeculoplasty.
After selective laser trabeculoplasty patients were prescribed non
steroidal anti Inflammatory drops and anti glaucoma drugs were
continued for 5 days. Soon after which patients were reviewed, anti
glaucoma drugs were stopped and evaluation was done after 2 weeks.
Blood pressure measurement done and hypertensives were
referred to hypertension clinic.
Random blood sugar levels measured, if found high diabetologist
opinion was obtained.
Patients diagnosed to have connective tissue disorders were under
the care of Rheumatologist.
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OBSERVATION AND ANALYSIS
68 eyes of 43 patients were taken into study. Two patients were
one eyed. one had leucomatous corneal opacity and other patient  had
evisceration done in one eye. Rest of the 16 eyes were not involved.
Steroid induced glaucoma resolved in 17 eyes of 13 patients with their
stoppage of steroids and with initiation of medical treatment.
1. AGE DISTRIBUTION
Ages of the patients studied varied from14-65 years. There was
no age preponderance. Predisposed patients were generally above the
age of 40 years. The maximum age of incidence was between 51-60
years. Steroid use was more in older age groups for various medical
ailments. This was similar to the studies conducted earlier44.
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2. SEX
Among the 43 patients 22 were male and 21 were female. There
was no sex preponderance. In the study group 51% were male 49% were
female.
Sex
51.2%
48.8%
Male
Female
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3. VISUAL ACUITY (VA)
Visual Acuity was normal (6/6) in 25% (17 eyes) of the cases.
8 eyes had vision less than 5/60 (11.8%).Among those 8 eyes, 1 eye had
Posterior Capsular Opacification,2 eyes had severe posterior
subcapsular cataract, 5 eyes had Glaucomatous optic atrophy. In
6(8.8%) eyes visual acuity was defective due to lens changes and in 37
(54.4%) eyes it was due to refractive error.
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4. IOP DISTRIBUTION
Average IOP on presentation was between 21-30mm of Hg
(42.6%) in 29 eyes. 10 eyes (14.7%) the IOP was below 20mm of Hg
These patients had glaucomatous damage. They had already stopped
applying steroid before presentation.IOP measured was similar to the
previous studies.44
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5. DISTRIBUTION OF RISK FACTORS
5 patients were hypertensives, 4 patients were Myope, 4 were
case of Rheumatoid Arthritis, 1 patient had Diabetes Mellitus and
Rheumatoid Arthritis, 3 patients had Diabetes Mellitus, 3 patients had
Diabetes Mellitus and Hypertension, 1 patient had Primary open Angle
Glaucoma and Diabetes Mellitus, 1 patient had dermatomyositis and 1
patient had polymyositis. Diabetes mellitus was the major risk factor in
our study.This was similar to previous studies.44
Risk Factor (RF)
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D - Dermato Myositis
DM  - Diabetes mellitus
HT  - Hypertension
RA - Rheumatoid Arthritis
MY - Myope
PM - Poly Myositis
POAG - Primary Open Angle Glaucoma
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6. TYPE OF STEROID USED
(41.2%) 14 patients (28 eyes) were on oral steroids.(4.4%) 3
patients had posterior subtenon injection.(2.9%) 2 patients intravitreal
triamcinolone was given. (51.5%) 24 patients (35 eyes) were on topical
medication alone. As per studies patients on  topical medication are
more prone for steroid induced glaucoma.42,43
2 2.9
24
35.4
2 2.9 2 2.9 1 1.5 1 1.5
16
23.5
18
26.5
2 2.9
0
5
10
15
20
25
30
35
40
N
o.
 o
f p
at
ie
nt
s
IVT O O&I O&TF PST TB TD TP TP&PST
Type of Steroid
Frequency Percentage
IVT - Intra Vitreal triamcinolone
O - Oral
O & T - Oral and Injectable
O&TF - Oral and Topical Fluoromethalone
PST - Posterior Sub Tenon
TB - Topical betnesol
TD - Topical Dexamethasone
TP - Topical Prednisolone
44
7. REASON FOR STEROID USE
 The most common reason for steroid induced glaucoma in our
study was, following cataract surgery. 20 patients (41.2%) had under
gone cataract surgery, of which 12 patient had undergone cataract
surgery in only one eye. Rest 8 patients  had undergone cataract surgery
in both the eyes. As per studies done allergic conjunctivitis was the most
common reason for steroid induced glaucoma.42,43
Reason for Steroid use
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AC - Allergic Conjunctivitis
AHA - Autoimmune Hemolytic Anaemia
BA - Bronchial Asthma
CME/CR - Cystoid Macular edema due to central retinal
Vein occlusion
CO - Chronic obstructive pulmonary disease
D - Dermato myositis
DCR - Dacro Cysto Rhinostomy
DR - Diabetic Retinopathy
NK - Nummular Keratitis
P - Post Operative
PM - Poly Myositis
PP - Pars Planitis
RA - Rheumatoid Arthritis
RV - Retinal Vasculitis
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8. DURATION OF STEROID
Average duration of steroid in years, less than 1 year – 41.5% in
27 eyes and above 6 years (13.8%) in 9 eyes. For 2 Patients one dose of
intravitreal triamcinolone was given, of which one was for cystoid
macular edema due to central retinal vein occlusion, and for the another
patient intravitreal triamcinolone was given for Diabetic Retinopathy. 3
patients were injected with  posterior subtenon injection of which 2 were
given for Parsplanitis and 1 for Retinal vasculitis.
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9. OPTIC NERVE HEAD CHANGES
The average cup disc ratio was normal 0.3(26.5%) in 18 eyes.5
patients had glaucomatous optic atrophy
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VASCULAR SIGNS
Fundus Findings No. of Eyes Percentage
Nasalisation of Vessels 48 70.5%
Bayonetting 32 47.1%
Laminar Dot Sign 46 67.6%
Baring of Circumlinear Vessels 6 2.9%
Splinter Hemorrhage 2 2.9%
Peripapillary Atrophy 24 35.3%
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10. FIELD DEFECTS DISTRIBUTION
(36.8%) 25 eyes of patients in this study were found to be normal.
18 eyes had tubular field (26.8%), Inferior arcuate defects were found in
7 eyes (10.3%), Superior Arcuate  defects were found in 3 eyes(4.4%).
In 5 eyes (7.4%) Automated perimetry was not possible due to poor
co-operation. Steroid induced glaucoma patients normally have field
defects similar to Primary open angle glaucoma1
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11. TREATMENT
38 eyes had medical management of glaucoma. Depending upon
IOP on presentation antiglaucoma medications were given. Based on
Optic nerve head changes and follow up IOP (done after 3 weeks),
antiglaucoma medications were  either continued or stopped. Surgical
treatment was done for 12 eyes, cataract extraction along with
trabeculectomy was done for 7 eyes, Trabeculectomy alone was done
for 5 eyes. Medical management followed by selective laser
trabeculoplasty was carried out for 18 eyes.
Treatment
18
12
38
M S SLT
SLT - Selective Laser Trabeculoplasty and Medication
S - Trabeculectomy
M  - Medication
POST OPERATIVE PICTURE SHOWING FILTERING BLEB
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12. FOLLOW UP IOP
The average follow up IOP was between 17  and 20 mm of Hg. In
equal percentage of patients the follow up IOP was less than 12 mm of
Hg. when the IOP on presentation was high  (above 30), oral
acetazolamide was given 250 mg BD, oral glycerol 30 ml TDS,
intravenous injection of mannitol 200 ml BD, and topical medication of
0.5% BD timolol was given. Once the IOP was reduced medicines were
gradually stopped or continued depending upon the glaucomatous
changes.
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13. STEROID INDUCED GLAUCOMA ALONG WITH
CATARACT
14 eyes of 7 patients had post subcapsular opacity. 2 patients
underwent cataract extraction with trabeculectomy. Lens changes were
not compromised in of the 5 patients. Those who presented with cataract
and glaucoma were all on oral steroids. Among the 7 patients, 3 patients
had Rheumatoid Arthritis, 1 patient had Rheumatoid Arthritis and
Diabetes mellitus. 1 patient was a case of Dermatomyositis, and 2
patients were Bronchial Asthmatics.
MAINTENANCE ON STEROIDS:
4 patients were on maintenance dose.3 patients of Rheumatoid
Arthritis were on maintenance dose of tablet prednisolone. 1 patient of
Dermatomyositis was also on maintenance dose of steroid. Selective
laser trabeculoplasty has been performed for all these four patients and
they are now on medical therapy.  While 2 patients of Bronchial Asthma
were on oral steroid  only during exacerbation in winter season. Among
these two patients surgery has been performed for one and the other
patient is awaiting surgery.
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DIURNAL VARIATION TEST
Once the diagnosis was made for Steroid induced glaucoma,
Patients were started with medication, following which diurnal variation
test was performed. In group I where 17 eyes of 13 patients were
examined showed a mean diurnal variation of IOP as 3.1 mm of Hg In
group 2 where 51 eyes of 30 patients were examined showed a mean
diurnal variation of IOP as 5.4 mm of Hg. All the patients were followed
up periodically. Disease progression was more in group 2 patients. Due
to initiation of medication the mean diurnal variation of IOP was less
than 10mm of Hg is both the groups.
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14. COMPARISON OF IOP BEFORE AND AFTER
TREATMENT
            There was a significant difference in IOP before and after
treatment. The values were compared by paired t test. The P value was
<0.001, suggesting that the test is significant. The mean IOP on
presentation was 31.10 mm of Hg and the mean follow up IOP was
15.59 mm of Hg.
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Mean StandardDeviation
‘ P ’
Value
IOP on Presentation 31.1 10.951
Follow up IOP 15.59 3.841
< 0.001
NOTE:     P value <0.001 denotes significance at 1% level
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15. PLASMA CORTISOL
         Plasma Cortisol levels were measured for 10 patients at 8 AM and
8 PM. The mean of values taken at 8 A.M in the morning was 13.7190.
The mean of values taken at 8 p.m. was 6.9219. All the values found at
8 A.M. and 8 P.M. were within normal limits, showing that there is no
effect of plasma cortisol in steroid induced glaucoma. Morning (8 A.M)
values were greater than the evening (8 P.M) values. Morning (8 A.M)
values compared with 8 p.m. (evening values) by t test showed
significant variation with p value ‘0.012’.Plasma cortisol levels were not
elevated because the patients in our study were already on medication
when the test was performed.
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Note:  P value of 0.012 denotes significance at 5% level.
Mean StandardDeviation
‘ P ’
Value
Plasma Cortisol
8 AM
13.7190 6.00
Plasma Cortisol
8 PM
6.9219 3.90
0.012
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16.  COMPARISON OF IOP BEFORE AND AFTER SLT
The patients were treated medically with single drug before SLT.
The aim of SLT was to provide benefit of reducing IOP similar to
medication. So that patients need not apply topical medication.
The mean IOP before SLT was 17.37mm of Hg, the mean IOP
after SLT was 19.26mm of Hg. This was because the antiglaucoma
drugs were stopped three weeks in prior to the measurement of IOP. IOP
of 18 eyes of 10 patients  were compared with paired t test. P value was
0.283 suggesting that it was not significant. There by implying SLT did
not bring down IOP to desired levels to prevent further disc damage.
This was not consistent with the previous studies because, certain
patients with connective tissue disorders were on maintenance dose of
steroids, while others had advanced glaucomatous changes. These
patients were followed up for a period of three months after SLT.
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After SLT 19.26 5.086
0.283
Note: P value of  0.283 suggest that it is not significant.
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SUMMARY
-   Steroid induced glaucoma resolved in 17 eyes of 13 patients
with their stoppage of steroids  and with initiation of medical
treatment.
- The average age of presentation in the study was 51-60 yrs.
- There was no sex preponderance, males and females were equally
affected.
- 17 eyes (25%) had normal vision  6/6 . 8 eyes (11.8%) had low
vision less than 5/60.
- The average IOP at presentation was between 21-30 mm of Hg in
29 eyes (42.67%).The IOP was below 20 mm of Hg in 10 eyes
(14.7%), 31-40 mm of Hg in 19 eyes (27.9%) and above 40 mm
of Hg in 10 eyes (14.7%).
- The various risk factors in the study were diabetes melllitus,
Hypertension, Rheumatoid Arthritis, Myopia. Diabetes mellitus
constituted about 30% among the risk factors.
- 51.5% of patients were on topical medication alone.
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- 41.2 % of patients developed steroid induced glaucoma following
continued usage of topical steroid medication after cataract
surgery.
- Two patients in our study who were given intravitreal
triamcinolone had to undergo trabeculectomy, such cases were
not seen in previous studies.
- Average duration of steroid use in years was less than 1 yr
(41.5%).
- 13 eyes (19%) had cupping value of 0.9
- 18 eyes (26.5%) had CD ratio of 0 .3 .
- 48 eye (70.5%) showed nasalisation of the vessels and was
observed to be the most common vascular sign.
- 18 eyes (26.5%) had tubular field.
- 25 eyes (36.8%)fields in automated perimetry was found to be
normal.
- 38 eyes were treated with medication, 12 eyes were treated by
surgical means, 18 eyes were treated with both medication and
selective laser trabeculoplasty.
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- The average IOP after treatment was below 12 mm of Hg in 22
eyes (32.4%) and between 17 and 20 mm of Hg 22 eyes (32.4%).
- 7 patients had posterior subcapsular cataract in both the eyes and
all these 7 patients were on oral steroid therapy. 4 patients were
still on maintenance dose of steroids.
- In the diurnal variation test 17 eyes of 13 patients showed a mean
IOP of 3.1 mm of Hg.Glaucoma resolved in these patients with
stoppage of steroid.
- There was a significant difference in IOP before and after
treatment by medical or surgical means.
-  plasma cortisol levels doesnot show any correlation in steroid
induced glaucoma
- Selective laser trabeculoplasty was not effective in controlling
IOP unlike medical or surgical treatment.
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DISCUSSION
          Steroid-induced glaucoma is an iatrogenic secondary open angle
glaucoma, with decreased trabecular outflow causing a rise of
intraocular pressure.
An increase in IOP occurs in response to the local or systemic use
of corticosteroids, but the response varies among individuals. IOP
response usually takes 2 to 4 weeks after starting topical steroids,
though rarely there can be an acute rise of IOP within hours in
association with systemic use of steroid or adrenocorticotropic hormone
(ACTH). If the ocular hypertension is of a significant magnitude, not
recognized, and not treated, subsequent glaucomatous optic neuropathy
can develop (that is, steroid-induced glaucoma) In vernal
keratoconjunctivitis (VKC), steroid induced glaucoma is a common
complication as patients require long-term therapy and steroids are often
used to provide early relief of symptoms.
Recently, the popular use of intravitreal triamcinolone acetonide
(IVTA) for subretinal fluid, macular edema, and adjunctive therapy in
the treatment of choroidal neovascularization has led to an increased
incidence of corticosteroid-induced ocular hypertension and glaucoma.
In our study 2 patients were given intravitreal injection of
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triamcinolone. One for diabetic retinopathy with macular edema and the
other for macular edema due to central retinal vein occlusion. Both of
them under went trabeculectomy due to increased IOP on presentation,
as it could not be controlled with medication.
Pre-existing POAG, or a status of a first-degree relative with
POAG are important risk factors for corticosteroid-induced ocular
hypertension and glaucoma. Age may be a risk factor; increased risk
appears to occur in a bimodal distribution peaking first at age 6. As one
progresses through adulthood age may not be a factor until late adult-
hood when the risk again rises. Finally, those with connective-tissue
disease, type-1 diabetes mellitus, and high myopia should all be
considered to be high risk, and prudent follow up and monitoring is
mandatory during prolonged periods of corticosteroid use.
Evidence supports several independent potential mechanisms of
increased resistance to the outflow of aqueous humor that can act
synergistically to produce corticosteroid-induced ocular hypertension:
1. Accumulation of polymerized glycosaminoglycans in the
trabecular mesh work from reduced availability of Iysosomal
enzymes.
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2. Suppression of phagocytosis by trabecular endothelial cells with
resultant accumulation of trabecular debris and increased outflow
resistance.
3. Genetic influences, with possible upregulation of myocilin,
optineurin and other factors with resultant increase in aqueous
outflow resistance.
Diagnosis of steroid-induced glaucoma requires a high index of
suspicion and the questioning of patients specifically about their use of
steroid eye drops, ointments, skin preparations, and pills. History should
also include duration of steroid use, and family history of glaucoma.
Complete ocular examination should be done including measurement of
IOP, gonioscopy and optic disc evaluation. Fundus photographs and
optic disc imaging are desirable for documenting progression, though
not mandatory.
In individuals with an IOP more than 20% above their baseline
measurement, or in those for whom there is clinical or functional
evidence of damage to their optic nerve during or after treatment with
corticosteroids any or all of the following may be necessary to reduce
IOP.
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1. Determine if steroid use (in any form) is truly needed, stop or
taper steroids.
2. Reduce the concentration or dosage of the steroid.
3. Change to a steroid with a lesser propensity for IOP elevation
(e.g. fluorometholone, loteprednol, or rimexolone)
4. Switch to a topical nonsteroidal anti-inflammatory drug (e.g.
ketorolac 0.4%, diclofenac 0.1%)
5. Start antiglaucoma therapy.
6. Obtain baseline visual fields and/or optic nerve photography or
peripapillary retinal nerve fibre layer measurements, if
appropriate.
 If the IOP is at alarming levels (> 50 mmHg, even in the case of
an optic nerve that appears healthy), surgical intervention with either a
tube or a filter may be appropriate. Four patients in our study had IOP
greater than 50 mm of Hg on presentation. Now their IOP is under
control with medication. Among these three had advanced
glaucomatous cupping and they have been advised to undergo surgery
and the remaining one patient had normal fundus findings. These
surgeries are required in fewer than 2% of patients receiving an
intravitreal injection. Surgeons should consider a vitrectomy or the
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explantation of the steroid implant for patients who have received
intravitreal injections or intraocular implants of a corticosteroid.
Close and regular monitoring of the IOP of patients treated with
corticosteroids is required (especially those with a personal or family
history of POAG or steroid-induced glaucoma). The frequency of IOP
monitoring should match the patient's risk factors for steroid induced
spikes in pressure as well as the medication's potency, dosage, route of
administration, and half-life and the duration of treatment.
High-risk patients who receive intravitreal injections require
examinations one day and one week after treatment and at least monthly
follow-up examinations after the medication's cessation.41
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CONCLUSION
- In susceptible individuals and persons with risk factors, steroids
should be avoided or if required should be administered in smaller
doses.
- As per our study patients who underwent cataract surgery were
more affected due to continued application of topical steroids.
Topical steroid application should be stopped once the eye is
quiet. Alternatively post operative patients who are prone to
glaucoma should be prescribed preferably with non steroidal anti
inflammatory drugs. IOP should be measured regularly in these
individuals.
- In cases of advanced glaucomatous damage surgery will be a
better  option.
- Plasma cortisol does not correlate clinically in steroid induced
glaucoma patients.
- Selective laser trabeculoplasty is not effective in preventing
further glaucomatous damage.
- Selective laser trabeculoplasty helps in short term control of IOP.
68
FUTURE SCOPE:
Selective laser trabeculoplasty can be used in short term control
of IOP. It is useful in very old patients who are not amenable to surgery
and for those who are not willing for surgery.
Plasma cortisol levels can be measured more frequently once in
four hours to find out the association between plasma cortisol levels and
steroid induced glaucoma. It can also be carried out in larger number of
patients.
           Steroid provocative test will help in identifying the high steroid
responders in the general population. It can also be performed in
patients for whom intravitreal triamcinolone has to be given.
          Genetic studies may throw more light on the etiopathogenesis of
steroid induced glaucoma.
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PROFORMA FOR THE CLINICAL
ANALYSIS OF STEROID INDUCED GLAUCOMA
Name :
Age  : Sex : Address:
Phone No:
Glaucoma No:
Presenting Complaint:
Defective vision:
Headache:
Frequent  change of glasses:
RISK FACTORS: Tick Duration  Treatment
If
yes
Family History:
Diabetes Mellitus:
Hypertension:
High Myope:
Connective Tissue
                Disorder:
Primary open
Angle Glaucoma:
Type of Steroid:
Route of Steroid:
Duration of use:
Reason for use:
Past History :
Previous history of intraocular Surgery
BP:
Ocular Examination
V/A  (BCVA) RE LE
IOP:
CCT:
Anterior Segment:
Lens:
fundus :
Media :
C:D Ratio
Gonioscopy
Automated
Perimetry:
Reliability :
Defects :
Diurnal IOP Monitoring:
     Time RE LE
PlasmaCortisol(microgram/dl)
         8 AM
         8 PM
Blood Sugar( mg/dl):
Selective Laser Trabeculoplasty:
Pre laser IOP:
Post Laser IOP:
TREATMENT:
         Medical
        Surgical
Continuation of Steroids (if required):
Follow up:
Date  :
Drugs :
Compliance:
Visual Acuity:
IOP:
Anterior Segment:
Fundus :
Automated Perimetry:
Advice:
LIST OF SURGERIES PERFORMED
1. NATARAJAN 72/M 403061 19/8/09 LE IMC LE ECCE with   PCIOL
2. SARADHA 70/F 57710 30/9/09 RE MC RE ECCE with PCIOL
3. MEGHANATHAN 61/M 447098 30/3/10 LE MC LE ECCE with PCIOL
4. JOHN 60/M 451362 4/8/10 RE IMC RE SICS with PCIOL
5. LAKSHMI 28/F 451619 14/8/10 LE UPPER LID
CHALAZION
LE INCISION
AND CURETTAGE
6. ELUMALAI 65/M 423534 6/10/10 LE CHR.DAC LE DCT
7. MOHAMMED 46/M 4423122 18/10/10 RE PTERY CONJ RE PTERY WITH AUTOGRAFT
8. GOVINDAMMAL 67/F 455306 29/12/10 LE IMC LE SICS WITH    PCIOL
9. RAGAMMA 50/F 456103 29/1/11 REPSCC RE SICS WITH PCIOL
10. SAHAYARAJ 55/M 456444 24/2/11 LE IMC LE SICS WITH PCIOL
11. LAVANYA 37/F 427833 18/3/11 RE CHR DAC RE DCR
12. SENTHIL 24/M 458125 2/4/11
LE PARTIAL
THICKNESS LID TEAR
LE LID TEAR SUTURING
13. LOGANATHAN 62/M 458709 26/4/11 RE IMC RE SICS WITH PCIOL
14. MUTHUAMMAL 55/F 459765 10/5/11 LE IMC LE SICS WITH PCIOL
15. MARUDHAAMMAL 60/F 460636 28/5/11 LE IMC LE SICS WITH PCIOL
16. SINTHAIYA 58/M 348872 2/6/11 RE PANOPH RE EVISCERATION
17. NAGAMMAL 70/F 461436 18/611 RELAGOPH RE     TARSORRHAPHY
18. RANI 46/F 462611 2/7/11 RE PTERY RE PTERY EXCISION WITHAMNIOTIC MEMBRANE
19. PADMAVATHY 55/F 463571 13/8/11 RE IMC RESICS WITH PCIOL
20. SUBBRAYAN 60/M 463791 27/8/11 LEIMC LE SICS WITH PCIOL
21. SHANTHA 59/F 465267 1/10/11 LE IMC LESICS WITH PCIOL
22. KUMARESAN 65/M 423145 13/10/11 LE CORNEALTEAR LE CORNEAL TEAR SUTURINGDONE
23. VELU 60/M 465838 22/10/11 RE IMC RE SICS WITH PCIOL
24. VEERASWAMY 66/M 466393 12/11/11 RE IMC RE SICS WITH PCIOL
25. CHETTU 65/M 466938 26/11/11 LE PSCC LE SICS WITH PCIOL
ABBREVIATIONS
RE/LE ------------- RIGHT EYE / LEFT EYE
IMC ------------- IMMATURE CATARACT
MC ------------- MATURE CATARACT
PSCC ------------- POSTERIOR SUBCAPSULAR
CHR DAC ------------- CHRONIC DACRYOCYSTITIS
PTERY ------------- PTERYGIUM
CONJ                         -------------- CONJUNCTIVA
ECCE ------------- EXTRA  CAPSULAR
CATARACT EXTRACTION
SICS ------------- SMALL INCISION CATARACT
SURGERY
PCIOL ------------- POSTERIOR CHAMBER
INTRA OCULAR LENS
DCR ------------- DACRYO CYSTO RHINOSTOMY
DCT ------------          DACRYOCYSTECTOMY
PANOPH  ------------- PANOPHTHALMITIS
LAGOPH -------------- LAGOPHTHALMOS
MASTER CHART
KEY TO MASTER CHART
Sl.No Key Description
1 M Medication
2 TD Topical Dexamethasone
3 TB Topical Betnesol
4 TP Topical Prednisolone
5 TF Topical Fluorometholone
6 P Post Operative
7 T Tubular Field
8 DM Diabetes Mellitus
9 SA Superior Arcuate
10 IA Inferior Arcuate
11 D Dermatomyositis
12 L Selective Laser trabeculoplasty
13 O Oral
14 Na Nasal
15 F Fixation
16 RA Rheumatoid Arthritis
17 N Normal
18 My Myope
19 BA Bronchial Asthma
20 AC Allergic Conjunctivitis
21 NV No View
22 NP Not Possible
23 PM Polymyositis
24 S Trabeculectomy
25 I Injectable Steroids
26 PST Posterior SubTenon
27 HT Hypertension
28 HM Hand Movements
29 CFCF Counting Fingers
30 DR Diabetic Retinopathy
31 IVT Intravitreal Triamcinolone
32 CME Cystoid Macular Edema
33 AHA Auto Immune HaemolyticAnaemia
34 POAG Primary Open Angle Glaucoma
35 DCR Post Dacrocystorhinostomy
36 PL Perception of Light
37 NO PL No Perception of Light
38 PU Pseudophakia
39 PSCC Posterior sub capsular cataract
40 C Lens clear
41 IM Immature cataract
42 MC Mature cataract
43 H Phthisical eye
44 PP Pars planitis
45 CO
Chronic obstructive pulmonary
disease
46 RV Retinal vasculitis
47 NK Nummular keratitis


